FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma

British Journal of Haematology

Volumn 132, Issue 6, 2006, Pages 698-704

  Kumar, Shaji ^a   Raje, Noopur ^b   Hideshima, Teru ^b   Ishitsuka, Kenji ^b   Podar, Klaus ^b   Gouille, Steven Le ^b   Chauhan, Dharminder ^b   Richardson, Paul ^b   Munshi, Nikhil C ^b   Anderson, Kenneth ^b  

^a MAYO CLINIC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Drug resistance; Multiple myeloma; Novel therapeutics

Indexed keywords

3 (7 FLUORO 4H QUINAZOLIN 3 YL)PIPERIDINE 2,6 DIONE; CASPASE 8; CASPASE 9; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; MULTIPLE MYELOMA; PRIORITY JOURNAL; STROMA;

6-KETOPROSTAGLANDIN F1 ALPHA; APOPTOSIS; BONE MARROW CELLS; CELL ADHESION; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; DNA, NEOPLASM; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-6; MULTIPLE MYELOMA; SOMATOMEDINS; STROMAL CELLS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33644923230     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05946.x     Document Type: Article

References (18)

1. Anderson K.C. 2003 The role of immunomodulatory drugs in multiple myeloma Seminars in Hematology 40 23 32
2. Attal M. Harousseau J.L. Stoppa A.M. Sotto J.J. Fuzibet J.G. Rossi J.F. Casassus P. Maisonneuve H. Facon T. Ifrah N. Payen C. Bataille R. 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New England Journal of Medicine 335 91 97
3. D'Amato R.J. Loughnan M.S. Flynn E. Folkman J. 1994 Thalidomide is an inhibitor of angiogenesis Proceedings of the National Academy of Sciences of the United States of America 91 4082 4085
4. Damiano J.S. Cress A.E. Hazlehurst L.A. Shtil A.A. Dalton W.S. 1999 Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines Blood 93 1658 1667
5. Davies F.E. Raje N. Hideshima T. Lentzsch S. Young G. Tai Y.T. Lin B. Podar K. Gupta D. Chauhan D. Treon S.P. Richardson P.G. Schlossman R.L. Morgan G.J. Muller G.W. Stirling D.I. Anderson K.C. 2001 Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 98 210 216
6. Dredge K. Marriott J.B. Dalgleish A.G. 2002 Immunological effects of thalidomide and its chemical and functional analogs Critical Reviews in Immunology 22 425 437
7. Haslett P.A. Corral L.G. Albert M. Kaplan G. 1998 Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset Journal of Experimental Medicine 187 1885 1892
8. Hideshima T. Chauhan D. Shima Y. Raje N. Davies F.E. Tai Y.T. Treon S.P. Lin B. Schlossman R.L. Richardson P. Muller G. Stirling D.I. Anderson K.C. 2000 Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2943 2950
9. Hideshima T. Chauhan D. Richardson P. Mitsiades C. Mitsiades N. Hayashi T. Munshi N. Dang L. Castro A. Palombella V. Adams J. Anderson K.C. 2002 NF-kappa B as a therapeutic target in multiple myeloma Journal of Biological Chemistry 277 16639 16647
10. Jemal A. Tiwari R.C. Murray T. Ghafoor A. Samuels A. Ward E. Feuer E.J. Thun M.J. 2004 Cancer statistics, 2004 CA: A Cancer Journal for Clinicians 54 8 29
11. Kumar S. Gertz M.A. Dispenzieri A. Lacy M.Q. Geyer S.M. Iturria N.L. Fonseca R. Hayman S.R. Lust J.A. Kyle R.A. Greipp P.R. Witzig T.E. Rajkumar S.V. 2003 Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma Mayo Clinic Proceedings 78 34 39
12. Kumar S. Witzig T.E. Dispenzieri A. Lacy M.Q. Wellik L.E. Fonseca R. Lust J.A. Gertz M.A. Kyle R.A. Greipp P.R. Rajkumar S.V. 2004 Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma Leukemia 18 624 627
13. Kumar S. Raje N. Hideshima T. Ishitsuka K. Roccaro A. Shiraishi N. Hamasaki M. Yasui H. Munshi N.C. Richardson P. Figg W.D. Anderson K.C. 2005 Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs Leukemia 19 1253 1261
14. Mitsiades N. Mitsiades C.S. Poulaki V. Chauhan D. Richardson P.G. Hideshima T. Munshi N.C. Treon S.P. Anderson K.C. 2002 Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 99 4525 4530
15. Rajkumar S.V. Hayman S. Gertz M.A. Dispenzieri A. Lacy M.Q. Greipp P.R. Geyer S. Iturria N. Fonseca R. Lust J.A. Kyle R.A. Witzig T.E. 2002 Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma Journal of Clinical Oncology 20 4319 4323
16. Richardson P. Hideshima T. Anderson K. 2002a Thalidomide: emerging role in cancer medicine Annual Review of Medicine 53 629 657
17. Richardson P.G. Schlossman R.L. Weller E. Hideshima T. Mitsiades C. Davies F. LeBlanc R. Catley L.P. Doss D. Kelly K. McKenney M. Mechlowicz J. Freeman A. Deocampo R. Rich R. Ryoo J.J. Chauhan D. Balinski K. Zeldis J. Anderson K.C. 2002b Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 3063 3067
18. Singhal S. Mehta J. Desikan R. Ayers D. Roberson P. Eddlemon P. Munshi N. Anaissie E. Wilson C. Dhodapkar M. Zeddis J. Barlogie B. 1999 Antitumor activity of thalidomide in refractory multiple myeloma New England Journal of Medicine 341 1565 1571